Albendazole Sulphoxide Kinetic Disposition After treatment with different Formulations in Dogs.

DIB A; SUÁREZ, G.,; FARÍAS, C.,; CABRERA P; CASTRO, S.,; MORENO, L; LANUSSE, C.,; SÁNCHEZ BRUNI, SF,

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

WILEY-BLACKWELL PUBLISHING, INC

Año: 2011 vol. 34 p. 136 - 141

0140-7783

New therapeutic strategies based on the search of alternative formulations ofAlbendazole (ABZ) and Albendazole Suphoxide (ABZSO) are under currentdevelopment to optimise posology and antiparasite efficacy in dogs. In anincomplete block design nine dogs were randomly divided into three groups(n=6). Treatments were done in two phases as follows. Phase I: Group I(treatment A): animals received ABZ at 25 mg/kg of conventional formulation.Group II (treatment B), dogs received 25mg/kg of a modified poloxamer-ABZformulation. Group III (treatment C) animals were treated with ABZSO inequimolar amount to ABZ doses. After 21 days of wash-out period theexperiment was repeatead (Phase II). Blood samples were collected over 24hand subsequently analyzed by High Performance Liquid Chromatography.ABZSO and ABZSO2 were the analytes recovered in plasma. Significant higher(P<0.001) ABZSO AUC (+500%) and Cmax (+487%) values, were obtained forthe treatment C in comparison with treatments A and B. However, no statisticaldifferences on pharmacokinetic (PK) parameters were found betweenformulations A and B. In conclusion, the enhanced plasma concentration profileobtained for the ABZSO formulation used in treatment C, may contribute tooptimise the anthelmintic control in dogs.